Jorge Pedro Leguizamo MD

Hematology Director, Laboratory Director ,and Clinical Trials Sub-investigator at Georgia Cancer Specialists

698 Duluth HwySte 201Lawrenceville, GA 30046
Phone+1 770-822-0788
Fax+1 770-822-0326

Dr. Leguizamo is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Leguizamo's full profile Already have an account?

Summary

Jorge Leguizamo, MD is an Oncologist based in Lawrenceville, GA with a vast knowledge and experience in diagnosing and treating patients suffering from conditions such as amyloidosis, hematologic oncology, hereditary breast/ovarian cancer, myelodysplasia, and myelofibrosis. He completed his medical education in 1995 at Columbia University and continued further studies at Naval Medical Center in San Diego and National Capital Consortium. Throughout his career, he has made significant contributions to various scientific publications, particularly in the fields of atypical hemolytic uremic syndrome and solid tumors therapy. Dr. Leguizamo also received the CMS Meaningful Use Stage 1 Certification from NextGen Ambulatory EHR in 2013.

Education & Training

National Capital ConsortiumFellowship, Hematology and Medical Oncology, 1999 - 2002
Naval Medical Center (San Diego)Residency, Internal Medicine, 1997 - 1999
Naval Medical Center (San Diego)Internship, Internal Medicine, 1995 - 1996
Columbia University Vagelos College of Physicians and SurgeonsClass of 1995

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

GA State Medical License 2008 - 2028
NY State Medical License 1997 - 2026
MA State Medical License 2005 - 2009
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 2 Certification Total Outcomes Management (TOM), ReportingMD, Inc., 2014-2017
CMS Meaningful Use Stage 2 Certification NextGen Patient Portal, NextGen Healthcare, 2014-2017
CMS Meaningful Use Stage 2 Certification NextGen Patient Portal, NextGen Healthcare, 2014-2017

Publications & Presentations

PubMed

14 citations
Treatment preference and quality of life impact: ravulizumab vs eculizumab for atypical hemolytic uremic syndrome.
Teri J Mauch, Michael R Chladek, Spero Cataland, Shruti Chaturvedi, Bradley P Dixon
Journal of Comparative Effectiveness Research. 2023-09-01
5 citations
A phase I pharmacologic and pharmacogenetic trial of sequential 24-hour infusion of irinotecan followed by leucovorin and a 48-hour infusion of fluorouracil in adult p...
Maurice A. Wright, Geraldine Morrison, Pengxin Lin, Gregory D. Leonard, Dat Nguyen
Clinical Cancer Research. 2005-06-01
7 citations
A phase I study of 9-aminocamptothecin as a colloidal dispersion formulation given as a fortnightly 72-h infusion.
Jorge P. Leguizamo, Mary G. Quinn, Chris H. Takimoto, Michael D. Liang, Abdel Salam Attia Ismail
Cancer Chemotherapy and Pharmacology. 2003-06-18